HIKAL LTD. - 524735 - Closure of Trading Window
Intimation of closure of trading window pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201530-12-2022
30-12-2022
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Acquisition13-12-2022
HIKAL LTD. - 524735 - Reply To Clarification Sought By The Exchange
Reply to clarification sought by the Exchange with respect to increase in volume08-12-2022
HIKAL LTD. - 524735 - Clarification sought from Hikal Ltd
The Exchange has sought clarification from Hikal Ltd on December 8, 2022, with reference to Movement in Volume.The reply is awaited.08-12-2022
HIKAL LTD. - 524735 - Related Party Transactions Pursuant To Regulation 23(9) Of The SEBI (LODR) Regulations, 2015
Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half-year ended September 30, 202218-11-2022
HIKAL LTD. - 524735 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Updates
Announcement Under Regulation 30 Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201516-11-2022
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Submission of transcript of Earnings call for quarter and half year ended September 30, 2022 under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 201516-11-2022
HIKAL LTD. - 524735 - Intimation Under Regulation 30 Of SEBI (LODR) - Earnings Call Audio Recording Q2 FY23
Intimation Under Regulation 30 Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Earnings Call Audio Recording Q2 FY2309-11-2022
Q2FY23 Quarterly Result Announced for Hikal Ltd.
Pharmaceutical company Hikal announced Q2FY23 results: Revenue of Rs. 559 crore; YoY growth of 19% EBITDA of Rs. 70 crore PAT stood at Rs. 25 crores Hikal’s long-term credit rating is maintained at A+ by ICRA Pharmaceutical sales grew 4% YoY and stood at Rs. 290 crore as compared to Rs. 280 crore in Q2 FY22 Crop Protection sales grew by 42% at Rs. 269 crore as compared to Rs. 190 crore in Q2 FY22 Commenting on the results, Jai Hiremath, Executive Chairman, Hikal Ltd. said, “Hikal has recorded a steady performance in Q2 in line with earlier guidance of a sequential recovery as we continue to move towards resuming our strong growth trajectory. In Q2, we achieved the highestever quarterly revenue in the history of Hikal, backed by strong demand in our Crop Protection business. We continue to keep an eye on the macro-economic environment, any potential for supply chain disruption, rising energy costs and the ongoing geopolitical unrest. The Crop Protection business, with Rs 269 Crores revenues in Q2 FY23, witnessed a strong growth of 42% on a YoY basis on the back of robust demand from customers in both own products and CDMO segments. We expect this momentum to continue in the next few quarters. We have received several new enquires from global innovator companies which are at various stages of execution. The commissioning of the new Crop Protection multipurpose facility at Panoli, Gujarat will be in Q4 FY23 The Pharma division business revenue stood at INR 290 Cr registering a 4% growth on a YoY basis. Soft demand, as well as pricing pressures in the end market, continue to be a concern. We have commercialized two NCE advanced intermediate with large potential for global innovator companies. Cost improvement programs, softening of raw material prices and optimal product mix will improve margins going forward. Our new Animal Health multipurpose facility is expected to come on stream by the first half of next calendar year. Our efforts to develop alternate suppliers to reduce dependence on a single geography or vendor is on track and will help us in being a partner of choice to our global customers. To mitigate the increase in energy costs, we are further implementing renewable energy projects which will help reduce costs and lower our carbon footprint significantly. We are continuing our strategic transformation journey, ‘Pinnacle Program’. Ongoing initiatives will help to reach our bold aspiration of driving profitable as well as sustainable growth. Significant progress is being made in building capabilities in terms of resources as well as infrastructure. We expect to see a positive momentum in both businesses in the medium to long term.” Result PDF09-11-2022